A single-nucleotide polymorphism in the 116C/G gene promotor for XBP-1 has also been identified as a potential risk for bipolar disorder which affected sensitivity to mood stabilizing treatments such as lithium [14]; however, another study found no such link [15]. The gene discussed is XBP1; the disease is bipolar disorder.